Table 2.
Summary of treatment-emergent adverse events of particular interest due to MGN1703 mechanism of action
| AE, number of patients (%) | MGN1703 (N = 43) | Placebo (N = 13) | ||
|---|---|---|---|---|
| Grade 1/2 | Grade 3/4 | Grade 1/2 | Grade 3/4 | |
| Flu-like symptoms | 6 (13.9) | – | 1 (7.7) | – |
| General pain | 4 (9.3) | – | 1 (7.7) | – |
| General rash, itching, paraesthesia | 4 (9.3) | – | – | 1 (7.7) |
| Injection-site reaction | 2 (4.6) | – | 1 (7.7) | – |
| Atypical pneumonia | 2 (4.6) | – | – | – |
| Polyneuropathy | 1 (2.3) | 1 (2.3) | – | – |
| ANA increased | 1 (2.3) | – | 1 (7.7) | – |
| Fatigue | 1 (2.3) | – | – | – |
| Hypertension | 1 (2.3) | – | – | – |
AE adverse event, ANA antinuclear antibody